IVERIC bio, Inc.

DB:O2T Stock Report

Market Cap: €5.0b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IVERIC bio Management

Management criteria checks 2/4

IVERIC bio's CEO is Glenn Sblendorio, appointed in Jul 2017, he has a tenure of 6.17 years. His total yearly compensation is $9.82M , comprised of 7.1% salary and 92.9% bonuses, including company stock and options. He directly owns 0.17% of the company’s shares, worth €8.69M. The average tenure of the management team and the board of directors is 5.5 years and 4.6 years respectively.

Key information

Glenn Sblendorio

Chief executive officer

US$9.8m

Total compensation

CEO salary percentage7.1%
CEO tenure6yrs
CEO ownership0.2%
Management average tenure5.5yrs
Board average tenure4.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Glenn Sblendorio's remuneration changed compared to IVERIC bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$223m

Dec 31 2022US$10mUS$700k

-US$185m

Sep 30 2022n/an/a

-US$159m

Jun 30 2022n/an/a

-US$141m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$665k

-US$115m

Sep 30 2021n/an/a

-US$107m

Jun 30 2021n/an/a

-US$108m

Mar 31 2021n/an/a

-US$96m

Dec 31 2020US$4mUS$640k

-US$85m

Sep 30 2020n/an/a

-US$77m

Jun 30 2020n/an/a

-US$66m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$2mUS$599k

-US$59m

Sep 30 2019n/an/a

US$63m

Jun 30 2019n/an/a

US$62m

Mar 31 2019n/an/a

US$64m

Dec 31 2018US$1mUS$625k

US$63m

Sep 30 2018n/an/a

-US$51m

Jun 30 2018n/an/a

US$153m

Mar 31 2018n/an/a

US$144m

Dec 31 2017US$3mUS$560k

US$114m

Sep 30 2017n/an/a

US$57m

Jun 30 2017n/an/a

-US$192m

Mar 31 2017n/an/a

-US$200m

Dec 31 2016US$9mUS$373k

-US$193m

Compensation vs Market: Glenn's total compensation ($USD9.82M) is above average for companies of similar size in the German market ($USD2.82M).

Compensation vs Earnings: Glenn's compensation has increased whilst the company is unprofitable.

CEO

Glenn Sblendorio (67 yo)

6yrs

Tenure

US$9,816,150

Compensation

Mr. Glenn P. Sblendorio, M.B.A., served as the President of IVERIC bio, Inc. (formerly, Ophthotech Corporation) since February 1, 2017 until May 01, 2021 and has been its Chief Executive Officer since July...

Leadership Team

NamePositionTenureCompensationOwnership
Glenn Sblendorio
CEO & Director6yrsUS$9.82m0.17%
€ 8.7m
Pravin Dugel
President & Director2.2yrsUS$4.63m0.15%
€ 7.4m
David Carroll
Senior VP6.3yrsUS$2.68m0.032%
€ 1.6m
Keith Westby
Senior VP & COO6.5yrsUS$2.66m0.029%
€ 1.4m
Christopher Simms
Senior VP & Chief Commercial Officer1.9yrsUS$2.67m0.024%
€ 1.2m
Samir Patel
Co-Founder and Consultant16.5yrsno datano data
Xiao-Ping Dai
Chief Technical Officer2.5yrsno datano data
Kathy Galante
Senior VP of Investor Relations & Corporate Communicationsno datano datano data
Todd Anderman
Senior VP5.4yrsno datano data
Amy Sheehan
Senior VP & Chief Human Resources Officer5.5yrsno datano data
Evelyn Harrison
Senior VP & Chief Clinical Operations Officer7.5yrsUS$411.67kno data
Guangping Gao
Chief Strategist of Gene Therapy3.7yrsno datano data

5.5yrs

Average Tenure

58yo

Average Age

Experienced Management: O2T's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Glenn Sblendorio
CEO & Director6.2yrsUS$9.82m0.17%
€ 8.7m
Pravin Dugel
President & Directorless than a yearUS$4.63m0.15%
€ 7.4m
Axel Bolte
Independent Director15.9yrsUS$354.59k0.016%
€ 801.9k
Adrienne Graves
Independent Chairman of the Board4.6yrsUS$398.34k0.016%
€ 801.9k
Mark Blumenkranz
Independent Director3yrsUS$354.59k0.023%
€ 1.2m
Carl Regillo
Member of Scientific Advisory Boardno datano datano data
Calvin Roberts
Independent Director4.5yrsUS$365.84k0.034%
€ 1.7m
Jane Pritchett Henderson
Independent Director5.5yrsUS$385.84k0.016%
€ 801.9k
Anat Lowenstein
Member of Scientific Advisory Boardno datano datano data
Jeffrey Heier
Member of Scientific Advisory Boardno datano datano data
Peter Kaiser
Member of Scientific Advisory Boardno datano datano data
Adnan Tufail
Member of Scientific Advisory Boardno datano datano data

4.6yrs

Average Tenure

64yo

Average Age

Experienced Board: O2T's board of directors are considered experienced (4.6 years average tenure).